Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetac…

December 21, 2010 By Bio-Medicine.Org

DEERFIELD, Ill. and OSAKA, Japan, Dec. 21, 2010 /PRNewswire/ —
Takeda Pharmaceutical Company Limited (“Takeda”) today announced
that Takeda and its wholly-owned subsidiary, Takeda Pharmaceuticals
North America, Inc. (“TPNA”), have completed settlements with all
defendants in patent litigation brought against the companies in
response to their Abbreviated New Drug Applications (“ANDAs”) for
generic ACTOS® (pioglitazone HCl), ACTOplus met®
(pioglitazone HCl and metformin HCl), and duetact®
(pioglitazone HCl and glimepiride). Takeda filed the lawsuits to
enforce several patents that expire in 2016 relating to ACTOS,
ACTOplus met, and duetact.

Agreements have been reached with the following generic
companies and their respective affiliates: Mylan, Inc. (“Mylan”),
Alphapharm Pty. Ltd. (“Alphapharm”), Watson Pharmaceuticals, Inc.
(“Watson”), Ranbaxy Laboratories Limited (“Ranbaxy”), Sandoz, Inc.
(“Sandoz”), Teva Pharmaceutical Industries, Ltd. (“Teva”), Torrent
Pharmaceuticals Limited (“Torrent”), Dr. Reddy’s Laboratories,
Limited (“Dr. Reddy”), Wockhardt Limited (“Wockhardt”), Synthon
Pharmaceuticals, Inc. (“Synthon”) and Breckenridge Pharmaceutical,
Inc. (“Breckenridge”) (collectively, “the Synthon defendants”), and
Aurobindo Pharma Limited (“Aurobindo”).

Based on these settlements, Takeda continues to operate in
accordance with its Mid-Range Plan, announced in May 2010, which
assumes that market entry of generic ACTOS will occur on August 17,
2012, and that market entry of generic ACTOplus met and
generic duetact will occur on December 14, 2012. With these
settlements, the forecasts of Takeda’s consolidated results for the
full year of fiscal 2010 announced on October 29, 2010 will not be
changed.

Takeda is the inventor and developer of ACTOS, which was
launched commercially in the United States (U.S.) in 1999 for the
treatment of type 2 diabetes and has been prescribed for more than
10

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech